Presidio Property Stock Quote SQFTP - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

15.73

Bid

15.71

Ask

15.75

Volume

1,283

15.67 Day's Range 15.85

0.00 52 Week Range 0.00

Market Cap

227.443M

Previous Close

15.70

Open

15.67

Last Trade

15.7

Last Trade Time

12:48:36

Financial Volume

$ 20,181

VWAP

15.73

Average Volume (3m)

Shares Outstanding

14,463,802

Dividend Yield

14.90%

PE Ratio

1.28

Earnings Per Share (EPS)

0.56

Revenue

17.64M

Net Profit

8.03M

Presidio Property Trust Inc is a real estate company. The company operates as a self-administered real estate investment trust. Presidio Property Trust's portfolio has diverse product types consisting of office, retail, industrial, self-storage, and residential properties. Its main objective is to m... Presidio Property Trust Inc is a real estate company. The company operates as a self-administered real estate investment trust. Presidio Property Trust's portfolio has diverse product types consisting of office, retail, industrial, self-storage, and residential properties. Its main objective is to maximize long-term stockholder value through the acquisition, management, leasing and selective redevelopment of high-quality office and industrial properties. Show more

Sector

Real Estate Investment Trust

Industry

Real Estate Investment Trust

Website

presidiopt.com

Headquarters

Baltimore, Maryland, USA

Founded

1970

Presidio Property Trust Inc is listed in the Real Estate Investment Trust sector of the NASDAQ with ticker SQFTP. The last closing price for Presidio Property was $15.70. Over the last year, Presidio Property shares have traded in a share price range of $ 0.00 to $ 0.00.

Presidio Property currently has 14,463,802 shares outstanding. The market capitalization of Presidio Property is $227.08 million. Presidio Property has a price to earnings ratio (PE ratio) of 1.28.

WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials

VANCOUVER, British Columbia, Oct. 15, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and...

VANCOUVER, British Columbia, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials

VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous T...

VANCOUVER, British Columbia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is excited to...

WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

VANCOUVER, British Columbia, Aug. 17, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, announces that...

WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, in celebration...

WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus

VANCOUVER, British Columbia, July 23, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...

WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066

VANCOUVER, British Columbia, July 06, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IMNNImunon Inc	$ 2.99 (151.26%)	118.98M
ATPCAgape ATP Corporation	$ 0.1629 (86.17%)	184.95M
ISPOInspirato Inc	$ 8.43 (60.88%)	25.04M
BFIBurgerFi International Inc	$ 0.63 (33.93%)	15.78M
PHARPharming Group NV	$ 8.735 (28.08%)	49.97k
QXOQXO Inc	$ 12.3092 (-79.65%)	15.37M
VBIVVBI Vaccines Inc	$ 0.1151 (-79.31%)	10.73M
BIMIBIMI International Medical Inc	$ 0.3939 (-66.04%)	2.1M
CNSPCNS Pharmaceuticals Inc	$ 0.4294 (-58.71%)	43.47M
BLMZBloomZ Inc	$ 1.68 (-34.63%)	549.77k
NVDANVIDIA Corporation	$ 105.05 (-5.86%)	296.15M
ATPCAgape ATP Corporation	$ 0.1629 (86.17%)	184.95M
SQQQProShares UltraPro Short QQQ	$ 9.4934 (4.90%)	130.93M
IMNNImunon Inc	$ 2.99 (151.26%)	118.98M
SOFISoFi Technologies Inc	$ 7.31 (-0.27%)	68.95M